Pantoprazole Prophylaxis Against Delayed CINV for Patients Receiving Breast Cancer Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

June 10, 2019

Primary Completion Date

October 15, 2021

Study Completion Date

October 15, 2021

Conditions
OncologyBreast CancerChemotherapy-induced Nausea and Vomiting
Interventions
DRUG

Pantoprazole 40mg

Proton pump inhibitor, drug action is to irreversibly block the hydrogen-potassium adenosine triphosphatase enzyme system (the 'proton pump') of the gastric parietal cell. This reduces basal and stimulated gastric acid secretion therefore raising gastric pH.

DRUG

Placebo

Matched placebo

Trial Locations (10)

3010

Rotorua Hospital, Rotorua

Unknown

Auckland City Hospital, Auckland

Christchurch Hospital, Christchurch

Dunedin Hospital, Dunedin

Waikato Hospital, Hamilton

Taranaki Base Hospital, New Plymouth

Palmerston North Hospital, Palmerston North

Tauranga Hospital, Tauranga

Wellington Hospital, Wellington

0148

Whangarei Hospital, Whangarei

All Listed Sponsors
lead

University of Auckland, New Zealand

OTHER

NCT03948477 - Pantoprazole Prophylaxis Against Delayed CINV for Patients Receiving Breast Cancer Chemotherapy | Biotech Hunter | Biotech Hunter